WG
BMRN icon

Winton Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Winton Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,720
Closed -$1.11M – 1128
2025
Q4 		$1.11M Sell
18,720
-104,754
-85% -$5.7M 0.04% 444
2025
Q3 		$6.69M Buy
123,474
+119,267
+2,835% +$6.82M 0.25% 102
2025
Q2 		$231K Sell
4,207
-12,734
-75% -$750K 0.01% 729
2025
Q1 		$1.2M Buy
16,941
+267
+2% +$18K 0.07% 273
2024
Q4 		$1.1M Sell
16,674
-4,639
-22% -$311K 0.07% 282
2024
Q3 		$1.5M Buy
21,313
+15,125
+244% +$1.26M 0.11% 164
2024
Q2 		$509K Buy
+6,188
New +$515K 0.03% 423
2023
Q4 		– Sell
-20,712
Closed -$1.83M – 746
2023
Q3 		$1.83M Buy
20,712
+16,494
+391% +$1.47M 0.15% 110
2023
Q2 		$366K Sell
4,218
-16,749
-80% -$1.58M 0.03% 454
2023
Q1 		$2.04M Buy
20,967
+1,612
+8% +$167K 0.12% 213
2022
Q4 		$2M Sell
19,355
-7,494
-28% -$704K 0.13% 202
2022
Q3 		$2.28M Sell
26,849
-8,504
-24% -$757K 0.15% 170
2022
Q2 		$2.93M Buy
35,353
+23,649
+202% +$1.88M 0.16% 174
2022
Q1 		$902K Buy
11,704
+2,164
+23% +$181K 0.05% 505
2021
Q4 		$843K Sell
9,540
-8,515
-47% -$703K 0.05% 518
2021
Q3 		$1.4M Buy
18,055
+6,098
+51% +$481K 0.08% 342
2021
Q2 		$998K Buy
11,957
+637
+6% +$50.5K 0.05% 526
2021
Q1 		$855K Buy
11,320
+3,120
+38% +$255K 0.05% 557
2020
Q4 		$719K Sell
8,200
-24,574
-75% -$1.95M 0.05% 595
2020
Q3 		$2.49M Sell
32,774
-22,949
-41% -$2.32M 0.08% 425
2020
Q2 		$6.87M Buy
55,723
+25,453
+84% +$2.53M 0.18% 113
2020
Q1 		$2.56M Buy
+30,270
New +$2.61M 0.07% 487
2017
Q4 		– Sell
-89,673
Closed -$8.35M – 665
2017
Q3 		$8.35M Buy
89,673
+87,223
+3,560% +$7.71M 0.27% 96
2017
Q2 		$223K Buy
+2,450
New +$223K 0.01% 587

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's BMRN Position: Q1 2026 in Review

Winton Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 18,720 shares — an estimated $1.11M sold.

Winton Group first reported a position in BMRN in Q2 2017 and held it in 24 quarters. The position peaked at $8.35M in Q3 2017. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Winton Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Winton Group sold 18,720 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.11M.
  • Winton Group first reported a position in BioMarin Pharmaceuticals in Q2 2017 and held it in 24 quarters.
  • Winton Group's BioMarin Pharmaceuticals position peaked at $8.35M in Q3 2017.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.